Activities of fluconazole, caspofungin, anidulafungin, and amphotericin b on planktonic and biofilm candida species determined by microcalorimetry

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2709-2717

  Maiolo, Elena Maryka ^a   Tafin, Ulrika Furustrand ^a   Borens, Olivier ^a   Trampuz, Andrej ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ECHINOCANDIN;

ACCURACY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DILUTION; FUNGUS GROWTH; HEAT; IN VITRO STUDY; MICROCALORIMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; BIOFILM; CALORIMETRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PLANKTON;

AMPHOTERICIN B; BIOFILMS; CALORIMETRY; CANDIDA; ECHINOCANDINS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; PLANKTON;

EID: 84898657164     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00057-14     Document Type: Article

References (46)

1. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. http://dx.doi.org/10.1128/CMR.00029-06.
2. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527. http://dx.doi.org/10.1128/JCM.42.4.1519-1527.2004.
3. Darouiche RO. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429. http://dx.doi.org/10.1056/ NEJMra035415.
4. Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. 2011. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat. Rev. Microbiol. 10:112-122. http://dx.doi.org/10.1038/nrmicro2711.
5. Corvec S, Portillo ME, Pasticci BM, Borens O, Trampuz A. 2012. Epidemiology and new developments in the diagnosis of prosthetic joint infection. Int. J. Artif. Organs 35:923-934. http://dx.doi.org/10.5301/ijao. 5000168.
6. Inigo M, Peman J, Del Pozo JL. 2012. Antifungal activity against Candida biofilms. Int. J. Artif. Organs 35:780-791. http://dx.doi.org/10.5301/ijao. 5000170.
7. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654. http://dx.doi.org/10.1056/NEJMra040181.
8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3 Clinical and Laboratory Standards Institute, Wayne PA.
9. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W, Eucast AFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
10. Chandra J, Mukherjee PK, Ghannoum MA. 2008. In vitro growth and analysis of Candida biofilms. Nat. Protoc. 3:1909-1924. http://dx.doi.org/10.1038/nprot. 2008.192.
11. Hawser SP, Douglas LJ. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39:2128-2131. http://dx.doi.org/10.1128/AAC.39.9.2128.
12. Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G. 2006. Antifungal agents: mode of action in yeast cells. Rev. Esp. Quimioter. 19:130-139.
13. Odds FC, Brown AJ, Gow NA. 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11:272-279. http://dx.doi.org/10.1016/S0966-842X(03)00117-3.
14. Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
15. Del Pozo JL, Frances ML, Hernaez S, Serrera A, Alonso M, Rubio MF. 2011. Effect of amphotericin B alone or in combination with rifampicin or clarithromycin against Candida species biofilms. Int. J. Artif. Organs 34: 766-770. http://dx.doi.org/10.5301/ijao.5000023.
16. Morace G, Borghi E, Iatta R, Montagna MT. 2009. Anidulafungin, a new echinocandin: in vitro activity. Drugs 69(Suppl 1):91-94. http://dx.doi.org/10. 2165/11315560-000000000-00000.
17. Chen SC, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41. http://dx.doi.org/10.2165/ 11585270-000000000-00000.
18. Spreghini E, Orlando F, Sanguinetti M, Posteraro B, Giannini D, Manso E, Barchiesi F. 2012. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob. Agents Chemother. 56:1215-1222. http://dx.doi.org/10.1128/AAC.05872-11.
19. Fiori B, Posteraro B, Torelli R, Tumbarello M, Perlin DS, Fadda G, Sanguinetti M. 2011. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob. Agents Chemother. 55:3031-3035. http://dx.doi.org/10.1128/AAC.01569-10.
20. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638. http://dx.doi.org/10.1128/EC.4.4.633-638. 2005.
21. Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Jr, Mowat E, Ramage G, Lopez-Ribot JL. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500. http://dx.doi.org/10.1038/ nport.2008.141.
22. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. 2003. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J. Clin. Microbiol. 41:506-508. http://dx.doi.org/10.1128/JCM.41.1.506-508.2003.
23. Lass-Florl C, Perkhofer S, Mayr A. 2010. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 53:1-11. http://dx.doi.org/10.1111/j.1439-0507.2009.01813.x.
24. Howell M, Wirz D, Daniels AU, Braissant O. 2012. Application of a microcalorimetric method for determining drug susceptibility in Mycobacterium species. J. Clin. Microbiol. 50:16-20. http://dx.doi.org/10.1128/JCM.05556-11.
25. Wadsö I. 2002. Isothermal microcalorimetry in applied biology. Thermochim. Acta 394:305-311. http://dx.doi.org/10.1016/S0040-6031(02)00263-0.
26. Wadsö I. 2001. Isothermal microcalorimetry: current problems and prospects. J. Therm. Anal. Calorim. 64:75-84. http://dx.doi.org/10.1023/A: 1011576710913.
27. Baldoni D, Hermann H, Frei R, Trampuz A, Steinhuber A. 2009. Performance of microcalorimetry for early detection of methicillin resistance in clinical isolates of Staphylococcus aureus. J. Clin. Microbiol. 47: 774-776. http://dx.doi.org/10.1128/JCM.02374-08.
28. Manneck T, Braissant O, Haggenmuller Y, Keiser J. 2011. Isothermal microcalorimetry to study drugs against Schistosoma mansoni. J. Clin. Microbiol. 49:1217-1225. http://dx.doi.org/10.1128/JCM.02382-10.
29. von Ah U, Wirz D, Daniels AU. 2009. Isothermal micro calorimetry-A new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMC Microbiol. 9:106. http://dx.doi.org/10.1186/1471- 2180-9-106.
30. Wenzler T, Steinhuber A, Wittlin S, Scheurer C, Brun R, Trampuz A. 2012. Isothermal microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and Plasmodium falciparum. PLoS Negl. Trop. Dis. 6:e1668. http://dx.doi.org/10.1371/journal.pntd.0001668.
31. Trampuz A, Salzmann S, Antheaume J, Daniels AU. 2007. Microcalorimetry: a novel method for detection of microbial contamination in platelet products. Transfusion 47:1643-1650. http://dx.doi.org/10.1111/j.1537-2995.2007.01336.x.
32. Furustrand Tafin U, Clauss M, Hauser PM, Bille J, Meis JF, Trampuz A. 2012. Isothermal microcalorimetry: a novel method for real-time determination of antifungal susceptibility of Aspergillus species. Clin. Microbiol. Infect. 18:E241-E245. http://dx.doi.org/10.1111/j.1469-0691.2012.03854.x.
33. Zhao Y, Yan D, Wang J, Zhang P, Xiao X. 2010. Anti-fungal effect of berberine on Candida albicans by microcalorimetry with correspondence analysis. Therm. Anal. Calorim. 102:49-55. http://dx.doi.org/10.1007/s10973-009-0565-7.
34. Kong WJ, Zhao YL, Xiao XH, Li ZL, Jin C, Li HB. 2009. Investigation of the anti-fungal activity of coptisine on Candida albicans growth by microcalorimetry combinedwithprincipalcomponentanalysis. J. Appl. Microbiol. 107:1072-1080. http://dx.doi.org/10.1111/j.1365-2672.2009.04292.x.
35. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. http://dx.doi.org/10.1128/ AAC.45.9.2475-2479.2001.
36. Furustrand Tafin U, Corvec S, Betrisey B, Zimmerli W, Trampuz A. 2012. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 56:1885-1891. http://dx.doi.org/10.1128/AAC.05552-11.
37. Furustrand Tafin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, Zimmerli W, Trampuz A. 2011. Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 55:4821-4827. http://dx.doi.org/10.1128/AAC.00141-11.
38. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. 2013. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-lactamase-producing Escherichia coli in a foreignbody infection model. Antimicrob. Agents Chemother. 57:1421-1427. http://dx.doi.org/10.1128/AAC.01718-12.
39. Bizerra FC, Melo AS, Katchburian E, Freymuller E, Straus AH, Takahashi HK, Colombo AL. 2011. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob. Agents Chemother. 55:302-310. http://dx.doi.org/10.1128/AAC.00633- 10.
40. Stevens DA, Espiritu M, Parmar R. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411. http://dx.doi.org/ 10.1128/AAC.48.9.3407-3411.2004.
41. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. 2011. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob. Agents Chemother. 55:2641-2647. http://dx.doi.org/10.1128/AAC.00999-10.
42. Stevens DA. 2009. Frequency of paradoxical effect with caspofungin in Candida albicans. Eur. J. Clin. Microbiol. Infect. Dis. 28:717. http://dx.doi.org/10.1007/s10096-008-0688-y.
43. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49: 973-980. http://dx.doi.org/10.1093/jac/dkf049.
44. Sanglard D, Ischer F, Bille J. 2001. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 45:1174-1183. http://dx.doi.org/10.1128/AAC.45.4.1174-1183.2001.
45. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679. http://dx.doi.org/10.1128/AAC.49.2.668-679.2005.
46. Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, Rohde B, Bauser C, Bader O, Sanglard D. 2009. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5:e1000268. http://dx.doi.org/10.1371/journal. ppat.1000268.